Oxford Science Enterprises and Cedars-Sinai Forge Health-Tech Partnership with Neu Health Investment
Deal News | Jan 29, 2025 | oxford sciences innovation
Oxford Science Enterprises (OSE) and Cedars-Sinai Intellectual Property Company have announced a significant new partnership to nurture health-tech start-ups in both the United States and the United Kingdom. This collaboration is marked by their inaugural co-investment of $2 million in Neu Health, a University of Oxford spin-out company. Neu Health is focused on delivering digital neurology care through a smartphone platform specifically designed to improve the treatment of Parkinson's disease and dementia. The strategic partnership will not only enhance the innovation pipeline between the US and UK health-tech markets but also leverage clinical insights to accelerate market entry and technology testing. Neu Health will now pilot its sophisticated app at the esteemed Cedars-Sinai in the US, introducing its platform to a new patient base with the aim of enhancing clinical outcomes. OSE, known for its focus on Health Tech, Deep Tech, and Life Sciences, sees this venture as a step toward addressing significant global challenges through scientific advancement.
Sectors
- Health-Tech
- Venture Capital
- Artificial Intelligence
Geography
- United Kingdom – Oxford Science Enterprises is based in the UK, and the article discusses the development and growth of health-tech start-ups from Oxford.
- United States – Cedars-Sinai, based in the US, partners with OSE to expand health-tech startups' reach and market entry in the US.
Industry
- Health-Tech – The primary focus of the article is on fostering growth and investment in health-tech start-ups, specifically through the co-investment in Neu Health, a digital neurology care provider.
- Venture Capital – Oxford Science Enterprises acts as a venture capital firm investing in transformative science and technology companies, particularly those emerging from Oxford University.
- Artificial Intelligence – Neu Health's platform utilizes AI to translate symptoms into actionable information for clinicians, highlighting the industry's reliance on advanced technology.
Financials
- $2 million – The investment made by Oxford Science Enterprises and Cedars-Sinai in Neu Health.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Oxford Science Enterprises | Investing Company | Private Equity Firm | An investment company focused on building science and technology companies from Oxford's research. |
| Cedars-Sinai Intellectual Property Company | Investing Company | Healthcare Provider | A division of Cedars-Sinai focused on intellectual property and health-tech innovation. |
| Neu Health | Target Company | Health-Tech Start-Up | A digital neurology care provider from the University of Oxford leveraging smartphone technology. |
| Shlomo Melmed | Executive Vice President and Dean at Cedars-Sinai | Person | Commented on the research partnership between Cedars-Sinai and OSE. |
| Heather Roxborough | Senior Partner at Oxford Science Enterprises | Person | Expressed excitement over the strategic partnership and its benefits for market entry. |
| James D. Laur | Chief Executive of Cedars-Sinai Intellectual Property Company | Person | Spoke on the aspirations for the partnership with OSE. |